Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A post-hoc analysis reveals that Abatacept significantly delays progression to Stage 2 or 3 Type 1 Diabetes specifically in individuals with higher baseline insulin secretion, marking a breakthrough in precision immunotherapy for early-stag
A dual-tracer study reveals that behavioral diet therapy provides greater postprandial glycemic improvement than Roux-en-Y gastric bypass after 20% weight loss in people with type 2 diabetes, driven by enhanced insulin-mediated glucose disp
Recent longitudinal and cross-sectional data reveal that patients with an evening chronotype face significantly higher risks of diabetic retinopathy and metabolic dysregulation, independent of traditional glycemic markers like HbA1c.
A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminu
Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various st
A nationwide SWEDEHEART study reveals that while second-generation drug-eluting stents have improved outcomes, patients with Type 1 and Type 2 diabetes remain at significantly higher risk for stent failure, with Type 1 patients facing a mor
The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduct
The Study of Drinks with Artificial Sweeteners (SODAS) randomized trial reveals that replacing habitual artificially sweetened beverages with water does not improve HbA1c levels in patients with type 2 diabetes, with the water group surpris
The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite k
A comprehensive analysis of the GRADE trial substudies reveals that adding basal insulin does not increase emotional distress in early T2DM and highlights the critical, predictive link between medication adherence and long-term glycemic suc
This randomized controlled trial demonstrates that a structured nurse-led education intervention significantly improves foot care knowledge and self-efficacy while reducing both the intention and actual behavior of delaying treatment in pat
A post hoc analysis of the DRCR Retina Network Protocol AA reveals that automated quantitative leakage index on ultra-widefield fluorescein angiography independently predicts the 4-year risk of DRSS worsening and vision-threatening complica
A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor
A nationwide cohort study of nearly 1 million Israeli males demonstrates that delayed puberty is independently associated with an increased risk of type 2 diabetes in early adulthood, suggesting it is a marker for long-term metabolic dysfun
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
Clinical trials and meta-analyses demonstrate that ANGPTL3 inhibitors, including SHR-1918 and zodasiran, provide superior LDL-C reduction compared to PCSK9 inhibitors in HoFH, particularly in patients with null-receptor genotypes where trad
A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patien
The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont
The IVAM-ED trial demonstrates that interactive virtual assistants significantly reduce mental distress and improve HbA1c levels in older adults with type 2 diabetes, highlighting a scalable solution for geriatric chronic disease management
A sub-analysis of the GRADE study reveals that beta-cell function (C-peptide index), rather than alpha-cell responses (glucagon), is the primary driver of glycemic durability in type 2 diabetes across various medication classes, suggesting
Open language-specific specialty feeds and department pages.